Abbot Healthcare signed a definitive agreement with Piramal Healthcare to acquire full ownership of Piramal’s domestic formulations, which manufactures generic drugs, for an up-front payment of $2.12 billion (Rs. 9,945 crore) and an additional $400 million (Rs.1,876 crore) to be paid annually for the next four years.